69812-30-2

Usage

Uses

Used in Pharmaceutical Industry:
5-Thiazolesulfonylchloride,2-(acetylamino)-(9CI) is used as a building block for the synthesis of various pharmaceutical products due to its ability to participate in a wide range of chemical reactions, making it a valuable intermediate in the development of new drugs.
Used in Organic Synthesis:
As a versatile intermediate, 5-Thiazolesulfonylchloride,2-(acetylamino)-(9CI) is used in organic synthesis for the preparation of thiazole and sulfonamide derivatives, contributing to the creation of diverse chemical compounds with potential applications in various fields.
Used in Dye and Pigment Production:
5-Thiazolesulfonylchloride,2-(acetylamino)-(9CI) also has potential applications as an intermediate in the production of dyes and pigments, where its unique chemical structure can contribute to the development of novel colorants for industrial use.

InChI:InChI=1/C5H5ClN2O3S2/c1-3(9)8-5-7-2-4(12-5)13(6,10)11/h2H,1H3,(H,7,8,9)

Upstream product

• 2719-23-5 2-acetamidothiazole 

Downstream Products

• 920313-42-4 C₇H₁₁N₃O₃S₂ 
• 1269500-26-6 C₂₀H₂₇N₅O₆S₂ 
• 1036386-11-4 N-{5-[3-(2-amino-4-ethoxy-pyrido[3,2-d]pyrimidin-6-yl)-phenylsulfamoyl]-thiazol-2-yl}-acetamide 
• 159895-68-8 3-(2-Acetamido-5-thiazolesulfonamido)-2-(2,4-dichlorophenyl)-1-(1H-1,2,4-triazol-1-yl)propan-2-ol 
• 82971-10-6 2-amino-1,3-thiazole-5-sulfonic acid 

Relevant academic research and scientific papers

CHEMICAL COMPOUNDS

The invention relates to a compound which is a thiazole derivative of Formula (I), or a pharmaceutically acceptable salt thereof, wherein R1, R2, R3, R4, R5, R6, R7, ?, Z, L, X,

cGAS ANTAGONIST COMPOUNDS

Disclosed are novel compounds of Formula (I) that are cGAS antagonists, methods of preparation of the compounds, pharmaceutical compositions comprising the compounds, and their use in medical therapy.

HYDRAZONE DERIVATIVE

A hydrazone derivative of formula [I]: wherein Ring A is aryl or heteroaryl, Ring T is heteroaryl or heterocycle, R1 and R2 are independently hydrogen atom, halogen atom, cycloalkylsulfonyl, etc., R3 and R4 comb

Synthesis of sulofenur analoges as antitumour agents: Part II

A series of N-aryl-N′-heteroaryl or N,N′-diheteroaryl sulfonylurea has been prepared using two different methods. All the intermediates were prepared including heteroarylsulfonyl chlorides and aryl- or hetero-arylurea derivatives. Structural elucidation of the newly synthesized compounds were based on elementary analysis, IR, 1H & 1C NMR and mass spectra. The antitumor screening of the prepared compounds were performed at the National Cancer Institute (NCI) Bethesda, Maryland, USA. Compound N-(3-methylbenzothiazol-2-yl)-N′ -(1-benzodiazolyl-sulfonyl)urea (13) with GI50, TGI, LC50 (MG-MID) values of 25.1, 77.5, 93.3 μM, respectively is the most active compound in this study. It showed a broad spectrum antitumor activity as well as selective activity toward individual cell lines. It showed distinctive activities compared to that of sulofenur against RPMI-8226 leukemia, EKVX Non-small lung cancer, PC-3 prostate cancer, OVCAR-4 Ovarian cancer, CAKI-1Renal cancer, MDA-MB-435 and T-47D Breast cancer with GI50 values of 21.5, 1.7, 28.7, 25.9, 15.9, 27.9, 15.1 μM, respectively.